BACKGROUND: Emerging evidence suggests that diabetes may increase the risk of cancers. However, available evidence on prostate cancer is conflicting. We therefore examined the association between Type 2 diabetes and risk of prostate cancer by conducting a detailed meta-analysis of all studies published regarding this subject. METHODS: PubMed database and bibliographies of retrieved articles were searched for epidemiological studies (published between 1970 and 2011), investigating the relationship between Type 2 diabetes and prostate cancer. Pooled risk ratio (RR) was calculated using random-effects model. Subgroup, sensitivity analysis and cumulative meta-analysis were also done. RESULTS: Forty-five studies (29 cohort and 16 case-control studies) involving 8.1 million participants and 132 331 prostate cancer cases detected a significant inverse association between Type 2 diabetes and risk of prostate cancer (RR 0.86, 95% confidence interval (CI) 0.80-0.92). For cohort studies alone, the RR was 0.87 (95% CI 0.80-0.94), and for case-control studies alone, the RR was 0.85 (95% CI 0.74-0.96). Sensitivity analysis done by excluding one outlier further strengthened our negative association (RR 0.83, 
INTRODUCTION
Type 2 diabetes has been associated with an increased risk of several cancers including pancreas, liver, breast, colorectal, urinary tract and female reproductive organs. 1 There is inconsistency in the reporting of prostate cancer risk in patients with Type 2 diabetes. There are two meta-analyses done earlier on the same subject by Bonovas et al. 2 and Kasper et al. 3 , reporting a statistically significant decrease in the risk of prostate cancer by 9% and 16%, respectively.
The most recent analysis done by Kasper et al. included 19 studies having 1 million population, including 20 373 prostate cancer cases. Twenty-six studies with conflicting results have been published after that meta-analysis, which raised the interest of adding new evidence to the previous analysis. Although this meta-analysis is an update of two previous meta-analysis, we have included studies published after 2006 (since the last analysis), which have shown conflicting results including decreased risk, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] increased risk [18] [19] [20] [21] [22] [23] [24] and some also reported no probable association. [25] [26] [27] We also performed an additional subgroup analysis of impact of ethnic variation and duration of diabetes with risk of prostate cancer. The strength of the present study lies in inclusion of data of large scale cohorts (sample size 430 000) having less chance of observational and recall bias thus population contributing to the present analysis is more than 8.1 million, including 132 331 prostate cancer cases.
Research conducted in recent years has also elucidated genetic linkage between Type 2 diabetes mellitus and prostate cancer. [28] [29] [30] The decreased risk of prostate cancer in patients with Type 2 diabetes cannot clearly be explained, but evidence suggests that metabolic factors associated with Type 2 diabetes has an impact on hypothalamic-pituitary-testicular axis, thereby resulting in hypogonadism. 1 However, the chance of detection bias before and after the advent of PSA testing cannot be ignored. The implementation of PSA testing may have changed the scope of disease that was diagnosed as prostate cancer. With the additional studies done in the PSA testing era, we are now able to do a subgroup analysis of men diagnosed before and after this time. The present study analyzed the risk of prostate cancer in patients with Type 2 diabetes along with subgroup analysis to establish possible variation of risk in different subgroups.
MATERIALS AND METHODS

Literature search
A comprehensive literature search was performed using PubMed (1 January 1970 through 31 July 2011) for observational cohort and case-control studies investigating an association between Type 2 diabetes and prostate cancer risk using keywords 'prostatic neoplasm, or prostatic cancer, or prostate cancer, and diabetes or diabetes mellitus'. We searched for additional studies in bibliographies and citation sections of retrieved articles. This study is reported in accordance with the Meta-analysis of Observational Studies in Epidemiology guidelines for meta-analysis of observational studies.
Study selection
Two members (GK and KU) independently reviewed the titles and abstracts of all identified citations according to the inclusion criteria. An abstract was judged relevant if it reported original data, was published in the English language and was from epidemiological studies (either cohort or casecontrol), where the outcome variable was prostate cancer and predictor variable was Type 2 diabetes (many studies did not differentiate between Type 1 and Type 2 diabetes, such studies were assumed to include patients with Type 2 diabetes only). Cohort studies reporting risk ratios (RRs) with 95% confidence intervals (CIs) and case-control studies reporting odds ratios with 95% CIs were included in the meta-analysis. The manuscripts were excluded, if the exposure was not Type 2 diabetes (that is, it was a metabolic syndrome or hyperglycemia or Type 1 diabetes), or the controls were not simply non-diabetes mellitus (that is, controls were BPH cases) or the outcome was not prostate cancer incidence or mortality (that is, it was prostate cancer recurrence), if no effect estimates were reported or not enough raw data for a RR to be calculated. If a manuscript included data on other cancers besides prostate cancer, we extracted the data on prostate cancer only. Any discrepancies were resolved by consensus in-group conference referencing the original article. When there were multiple publications for the same population, we included the data from the study which has largest sample size. We did not contact the authors of the original manuscripts for additional data.
Data extraction
Relevant data was extracted as shown in Table 1 . Data were extracted by one author (GK) and independently verified by another (KU).
Quality assessment
The quality of each study was assessed independently by two authors (GK, KU) by using Newcastle-Ottawa Scale (NOS). 32 We defined studies of high quality as those that scored the maximum nine stars on the NOS; studies of medium quality scored seven or eight stars.
Data synthesis and statistical analysis
The primary measure was RR of prostate cancer, calculated using the random-effects model (DerSimonian and Laird method), which accounts for heterogeneity among studies. As absolute risk of prostate cancer is low, the odds ratio in case-control studies mathematically approximates the RR; 3 therefore, we report all results as RRs. To assess heterogeneity among the studies, we used the Cochran Q and I 2 statistics; for the Q statistic, a Po0.10 was considered statistically significant for heterogeneity; for I 2 , a value 450% is considered a measure of severe heterogeneity. 33 Prespecified subgroup analysis was performed to assess the source of heterogeneity, according to (a) study design, (b) PSA era, (c) time frame of Kasper et al., (d) number of covariates adjusted, (e) adjusted for body mass index (BMI) and obesity, (f) study quality and (g) ethnicity. For subgroup b, we considered earlier than 1990 as the time when PSA screening was not commonly used ('pre-PSA') and 1990 or later as the era when this test was widespread ('PSA era'). To assess the robustness of the association, we also performed sensitivity analysis by excluding the outliers. 34 In addition, to assess the trend of reporting, cumulative meta-analysis was performed examining the influence of a single study on the summary risk estimate by adding one study in each turn. 35 The publication bias was assessed using funnel plot and Begg's test. 33 When data were not uniformly reported to allow formal statistical analysis, we present the data in a narrative format. All statistical tests were two-sided and Po0.05 was considered statistically significant, except where otherwise specified. Data were analyzed using STATA version 11.0 (StataCorp, College Station, TX, USA).
RESULTS
Search results
Search results were shown in Figure 1 .
We included Kasper et al. as a reference for studies included in Kasper et al. analysis. Original references of these studies are mentioned in Supplementary Materials.
Study characteristics
We identified 28 manuscripts reporting data from 29 cohort studies of Type 2 diabetes and risk of prostate cancer published between 1982 and 2011. These studies included 1 036 859 participants with Type 2 diabetes; participants were followed for 2-27 years, reporting a total of more than 116 000 incident cases of prostate cancer. Sixteen case-control studies published between 1971 and 2011 were also identified to be included in the analysis. A total of 1320 cases of prostate cancer were reported among 5468 patients with Type 2 diabetes, whereas 13 146 cases of prostate cancer were reported among 48 405 subjects without diabetes in these retrospective studies. There were eight population-based and eight hospital-based case-control studies. There were 37 studies conducted in western countries and 8 studies conducted in other parts of world, mainly Asian countries. The characteristics of the selected studies are presented in Table 1 .
Quality assessment When quality of included studies was assessed, there were 12 high, 22 medium and 11 low-quality studies (Table 1 ). With regard to cohort studies, 10 studies had a NOS score of 9. Together cohort studies have an average NOS score of 7.86. With regard to casecontrol studies, only two studies have a NOS score of 9. Together case-control studies have an average NOS score of 7.81.
Main analysis
As a significant heterogeneity was found (P heterogeneity o0.01, I 2 ¼ 87.6%), random-effects model was chosen over a fixed-effect model. We found Type 2 diabetes was associated with a significantly lower risk of prostate cancer compared with non-diabetic population (pooled RR, 0.86 (95% CI 0.80-0.92)). The multivariableadjusted RRs of prostate cancer for each study and all studies combined are shown in Figure 2 . Visual examination of the funnel plot revealed minimal asymmetry (data not shown), further confirmed by Begg's test (P ¼ 0.23) indicating little or no publication bias in our analysis. Table 2 presents the results of subgroup analyses stratified by characteristics of study designs and populations. When cohort studies were analyzed alone, the pooled RR was found to be 0.87 (95% CI 0.80-0.94). Using case-control studies alone, we found that the pooled RR was 0.85 (95% CI 0.74-0.96). Either cohort or case-control studies alone had a high degree of heterogeneity (P heterogeneity o0.01). Overall, the inverse association between Type 2 diabetes and risk of prostate cancer was not substantially modified by study design (P interaction ¼ 0.76).
Subgroup analysis
We determined that the pooled RR for the studies published in the same time frame as was included in Kasper et al. 3 was 0.84 (95% CI 0.76-0.92; P heterogeneity o0.01). We also did subgroup analysis of studies published after Kasper et al.'s analysis. The pooled effect estimate for this subgroup was 0.90 (95% CI 0.81-0.99; P heterogeneity o0.01). This indicates that there was heterogeneity in the studies that were either published before 2006 and studies published after this time frame.
To determine whether the effect estimate between Type 2 diabetes and prostate cancer changed after PSA screening was introduced as a common procedure, we did another subgroup analysis. The RR for pre-PSA was 0.87 (95% CI 0.82-0.93; P heterogeneity o0.01), and the RR for PSA era was 0.90 (95% CI 0.80-0.99; P heterogeneity o0.01), suggesting heterogeneity in this subgroup. We examined whether more thoroughly adjusting for potential confounders affected the pooled RR and degree of heterogeneity. The effect estimate for studies that adjusted five or more confounders was 0.87 (95% CI 0.79-0.94; P heterogeneity o0.01), again suggesting heterogeneity in this subgroup. Similar results were found if the subgroup included studies adjusting o5 covariates RR, 0.89 (95% CI 0.78-1.00). The effect of adjusting for BMI or obesity on the overall effect estimate was also evaluated. For the studies adjusting for BMI or obesity, RR was 0.87 (95% CI 0.81-0.94), and for the studies not adjusting for BMI or obesity, the RR was 0.90 (95% CI 0.80-1.00). We found a significant difference (P interaction ¼ 0.01) between pooled RR of western studies (RR, 0.81 (95% CI 0.76-0.85)) and Asian studies (RR, 1.64 (1.0-2.88)). Studies having better-quality scores (NOS score 48) showed a significant decreased risk of prostate cancer (pooled RR, 0.82 (95% CI 0.75-0.89)). The result was similar with studies having mediumquality (pooled RR, 0.86 (95% CI 0.74-0.97)) but not with lowquality scores (pooled RR, 1.02 (95% CI 0.88-1.17)).
There were limited and conflicting data on duration of Type 2 diabetes and risk of prostate cancer, which were not uniformly reported, making formal statistical analyses impossible. There were total 12 studies reporting data on duration of Type 2 diabetes and risk of prostate cancer. Two studies 10, 24 reported a positive association between Type 2 diabetes and risk of prostate cancer with increasing duration of Type 2 diabetes. However, seven studies [3] [4] [5] 8, 10, 26 reported decreased risk of prostate cancer with increasing duration of Type 2 diabetes and three studies 3, 13 reported no association of risk of prostate cancer with duration of Type 2 diabetes. Studies reported varied results on association between Type 2 diabetes and severity grade of prostate cancer. There were total 12 studies reporting data on association between Type 2 diabetes and grade of prostate cancer. Among the studies which reported negative association, three studies 7, 11, 13 suggested the negative association is more pronounced in low-grade prostate cancer, whereas two studies 1, 10 suggested that negative association is more pronounced in high-grade prostate cancer. Four studies 18, 21, 22, 26 concluded that positive association is more pronounced in high-grade prostate cancer. Three studies reported that there is no probable association between Type 2 diabetes and grade of prostate cancer. 3, 15, 27 A cumulative meta-analysis of total 45 studies was done to evaluate the cumulative effect estimate over time. In 1971, Wynder et al. 3 reported a nonsignificant effect estimate of 1.18. Between 1971 and 2010, 26 studies were published. In 2010, the cumulative RR reached 0.78. Between 2010 and 2011, 10 more publications were added cumulatively, resulting in overall effect estimate of 0.86. Sensitivity analysis showed a significant variation in pooled RR from 0.86 to 0.83 (95% CI 0.78-0.87) after removing the study by Tseng 24 (this was the study that has a significantly higher RR-5.83 compared to all other studies). However, the estimated effect size did not deviate much by excluding any of the other study one at a time (RR lies between 0.85 and 0.87).
DISCUSSION
The present updated pooled analysis of 45 studies currently available showed that patients with Type 2 diabetes were associated with an estimated reduction of 14% in the risk of developing prostate cancer as compared with those without diabetes. The result is further strengthened by the sensitivity analysis, whereby removing one study done by Tseng 24 showed a stronger inverse relationship of estimated 17% reduction in risk of prostate cancer in patients with Type 2 diabetes.
Our finding of decreased relative risk of prostate cancer in patients with diabetes is supported by genetic studies. [28] [29] [30] Research conducted in recent years has also elucidated genetic linkage between Type 2 diabetes mellitus and prostate cancer. Pierce et al. 30 reported that individuals with increased genetic susceptibility to Type 2 diabetes have decreased risk of prostate cancer. Meyer et al. 29 found significant association of 4 of the 13 Type 2 diabetes mellitus single-nucleotide polymorphisms and prostate cancer risk. However, they failed to show similar effect with Type 1 diabetes.
In our subgroup analyses, the results were not substantially affected by study design, PSA testing era, number of covariates adjustment and adjustment for BMI and obesity. The estimates were homogenous across studies of different designs, including cohort and case-control studies. No significant variation is seen in pre-PSA and PSA testing era. The multiple subgroup analysis showed that the results are robust. Performing sensitivity analysis by excluding study by Tseng showed a difference in pooled effect estimate. However, it further supports the inverse association prostate cancer and Type 2 diabetes mellitus. The possible explanation given by the author for the significant variation in study by Tseng 24 is the similar detection of cancer across different social classes because of the inclusion of large population in the study and waiver of medical copayments. However, the follow-up period of the study was very less (2 years), thus firm conclusions cannot be drawn from this study alone. We tried to contact the author for the possible explanation, which failed.
We found a significant increased risk (P interaction ¼ 0.01) of prostate cancer in Asian population when compared with western population that can be explained because of the difference in the distribution of the genotypes of AR, SRD5A2 and VDR gene among different ethnic population, which have an association with the risk of prostate cancer. 36 The present analysis has found a significant variation between the results of studies published before and after the last metaanalysis. 3 This can be explained by increased reporting of prostate cancer and the higher number of publications with larger sample size afterwards. Large number of prospective studies is included in the present analysis, thus providing strongest evidence till date.
Evidence regarding biological mechanisms behind decreased risk of prostate cancer in patients with diabetes mellitus is not fully delineated. This association can be explained by the change of insulin and testosterone levels in the body. Initially, many Type 2 diabetic men are hyperinsulinemic, but as the disease progress, the levels of insulin may decline. 3 Growth of both normal and cancerous prostate cells is positively associated with raised levels of insulin, and therefore, decreased insulin may have a growthinhibitory effect on these cells. 5 Insulin has also been shown to be a growth factor for prostatic epithelium in vitro, 37 to stimulate growth of a rat prostate cancer cell line in vitro, 38 and is associated with higher incident and recurrent prostate cancer. 39 Therefore, a reduced risk of developing prostate cancer in patients with longduration diabetes may be due to declining levels of circulating insulin. Similar results were seen in seven studies [3] [4] [5] 8, 10, 26 included in the present analysis reporting decreased risk of prostate cancer with increasing duration of Type 2 diabetes. 
41
Another established evidence of decreased levels of testosterone in diabetes is also there, which had been observed both in animal 40 and human studies. 41 High testosterone levels may be a risk factor for prostate cancer. 5 Therefore, low testosterone levels may have protective action. In prostate cells, testosterone is converted to the more active androgen, dihydrotestosterone. Both hormones bind to the androgen receptor, forming a complex that binds to DNA, increasing transcription and possibly proliferation of both normal and cancerous prostate cells. 42 The data available are insufficient to draw a conclusion on association between Type 2 diabetes and severity grade of prostate cancer. 43 Our meta-analysis has several limitations. First, we did not search for unpublished studies for original data. Second, the included studies were different in terms of study design, confounder adjustments, some studies did confirm the diagnosis of diabetes, most used self-report of diabetes as the predictor. A positive self-report for diabetes is generally quite accurate in epidemiologic studies. Most studies used age as a proxy criterion for Type 1 and Type 2 diabetes. Severity, duration and treatment of diabetes were also not reported in most studies. Finally, our analysis was restricted to articles in the English language, which may influence the results.
In conclusion, our analysis has shown that Type 2 diabetes is associated with moderately (14%) decreased risk of prostate cancer, which is consistent with previous meta-analysis. Although recent studies showed a positive association, the pooled overall risk estimated from all studies still showed a decreased risk of prostate cancer in patients with Type 2 diabetes. Future studies should focus on elucidating potential pathophysiologic links between diabetes and prostate cancer.
